The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years
- PMID: 22152188
- DOI: 10.1016/j.jval.2011.06.007
The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years
Abstract
Objectives: The National Institute for Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process in the United Kingdom was established in 2005 in order to provide guidance on new technologies as close to their launch as possible. The NICE recommended timeframe for completion of an STA is 34 weeks. The purpose of this study was to map the first 95 STAs to collect information on a range of issues including timelines and appraisal decisions.
Methods: A mapping tool was devised to collect information from the NICE Web site. Data were analyzed by calculating frequencies. Simple descriptive statistics were applied where appropriate.
Results: Ninety-five STAs were included in the analysis. Almost one-third (30/95) initially identified topics did not go on to be appraised often due to licensing issues. Timelines were measured for 29 completed STAs. Eight (28%) of these were completed by 37 weeks and 20 (69%) by 42 weeks. When STAs with appeals were excluded, 31% (8/26) were completed by 37 weeks and 85% (22/26) by 42 weeks. The incremental cost-effectiveness ratios reported by manufacturers were consistently lower than those estimated by the evidence review groups. In all, 76% (38/50) of the completed STAs resulted in an approval.
Conclusions: The NICE Web site enabled access to almost all necessary information, although electronic documents were sometimes difficult to locate. One-third of the referred topics were suspended or terminated. The NICE STA process is slower than initially anticipated and this is primarily due to events outside of NICE's direct control.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
Similar articles
-
The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.Health Technol Assess. 2016 Apr;20(26):1-48. doi: 10.3310/hta20260. Health Technol Assess. 2016. PMID: 27049841 Free PMC article.
-
Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.Health Technol Assess. 2011 May;15(22):1-82, iii-iv. doi: 10.3310/hta15220. Health Technol Assess. 2011. PMID: 21561569
-
Single technology appraisals by NICE: are they delivering faster guidance to the NHS?Pharmacoeconomics. 2008;26(12):1037-43. doi: 10.2165/0019053-200826120-00006. Pharmacoeconomics. 2008. PMID: 19014204
-
A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?J Med Econ. 2019 Mar;22(3):205-214. doi: 10.1080/13696998.2018.1547303. Epub 2018 Nov 30. J Med Econ. 2019. PMID: 30422080 Review.
-
Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.Pharmacoecon Open. 2018 Jun;2(2):97-107. doi: 10.1007/s41669-017-0040-5. Pharmacoecon Open. 2018. PMID: 29623616 Free PMC article. Review.
Cited by
-
New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.Pharmacoeconomics. 2018 May;36(5):613-624. doi: 10.1007/s40273-018-0632-7. Pharmacoeconomics. 2018. PMID: 29520603 Free PMC article.
-
Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process.Pharmacoecon Open. 2017 Jun;1(2):99-108. doi: 10.1007/s41669-016-0001-4. Pharmacoecon Open. 2017. PMID: 29442332 Free PMC article.
-
The Political Sociology of NICE: Investigating Pharmaceutical Cost-Effectiveness Regulation in the UK.Sociol Health Illn. 2025 Jan;47(1):e13878. doi: 10.1111/1467-9566.13878. Sociol Health Illn. 2025. PMID: 39743684 Free PMC article.
-
Key stakeholders' perspectives on a Web-based advance care planning tool for advanced lung disease.J Crit Care. 2015 Dec;30(6):1418.e7-1418.e12. doi: 10.1016/j.jcrc.2015.09.001. Epub 2015 Sep 3. J Crit Care. 2015. PMID: 26404957 Free PMC article.
-
A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process.BMJ Open. 2012 Feb 8;2(1):e000562. doi: 10.1136/bmjopen-2011-000562. Print 2012. BMJ Open. 2012. PMID: 22318664 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources